Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16300306 | 1.00 | POLB (0.30) | POLBPRKDC | |
| SCHEMBL16300286 | 0.94 | AKT1 (0.31) | PRKDC | |
| SCHEMBL4568666 | 0.94 | — | — | |
| SCHEMBL15458557 | 0.92 | — | — | |
| SCHEMBL15459689 | 0.92 | — | — | |
| SCHEMBL15459719 | 0.92 | — | — | |
| SCHEMBL15452315 | 0.91 | PRKDC (0.33) | PRKDC | |
| SCHEMBL15763599 | 0.90 | POLB (0.30) | POLBPRKDC | |
| SCHEMBL15763649 | 0.90 | POLB (0.30) | POLBPRKDC | |
| SCHEMBL15458486 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447224-B2 | Urethane (meth) acrylate monomer and production process thereof | TOKUYAMA CORPORATION (JP) | 2016-09-20 | — | — | US | disclosed |
| US-9447224-B2 | Urethane (meth) acrylate monomer and production process thereof | TOKUYAMA CORPORATION (JP) | 2016-09-20 | — | — | US | disclosed |
| US-8308996-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8308996-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| EP-2502945-A1 | URETHANE (METH) ACRYLATE MONOMER AND MANUFACTURING METHOD FOR SAME | Tokuyama Corporation (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20120228567-A1 | URETHANE (METH) ACRYLATE MONOMER AND PRODUCTION PROCESS THEREOF | TOKUYAMA CORPORATION (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120228567-A1 | URETHANE (METH) ACRYLATE MONOMER AND PRODUCTION PROCESS THEREOF | TOKUYAMA CORPORATION (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120121934-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120121934-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120228567-A1 | URETHANE (METH) ACRYLATE MONOMER AND PRODUCTION PROCESS THEREOF | MTDH, PAM, ACR | POLB 1440/4885PRKDC 1038/4885 |
| US-20120121934-A1 | CHROMENE COMPOUND | TST, CNOT1, CNOT9 | POLB 3324/4885PRKDC 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.